Comorbidity indices in observational studies on cancer risk

Borrelli AM, Spencer K, Birch RJ. Adjusting for comorbidity in observational cancer studies: a systematic review to assess alignment between index and study. Int J Oncol. 2023;62(1):9.

https://doi.org/10.3892/ijo.2022.5457 DOI: https://doi.org/10.3892/ijo.2022.5457

Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83.

https://doi.org/10.1016/0021-9681(87)90171-8 DOI: https://doi.org/10.1016/0021-9681(87)90171-8

Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care. 1998;36(1):8–27.

https://doi.org/10.1097/00005650-199801000-00004 DOI: https://doi.org/10.1097/00005650-199801000-00004

Kristensen KB, Lund LC, Jensen PB, Broe A, Rotbain E, Damkier P, et al. Development and validation of a Nordic Multimorbidity Index based on hospital diagnoses and filled prescriptions. J Clin Epidemiol. 2022;14:567–79.

https://doi.org/10.2147/CLEP.S353398 DOI: https://doi.org/10.2147/CLEP.S353398

Ljung R, Sundström A, Grünewald M, Backman C, Feltelius N, Gedeborg R, et al. The profile of the COvid-19 VACcination register SAFEty study in Sweden (CoVacSafe-SE). Ups J Med Sci. 2021;126: 1-11.

https://doi.org/10.48101/ujms.v126.8136 DOI: https://doi.org/10.48101/ujms.v126.8136

Kravutske H, Mansoorian S, Käsmann L, Lehmann J, Richlitzki C, Kauffmann-Guerrero D, et al. Real-world insights into moderately hypofractionated thoracic radiotherapy in elderly and multimorbid patients with stage II/III NSCLC: a retrospective study. Acta Oncol. 2025;64:957–65.

https://doi.org/10.2340/1651-226X.2025.43496 DOI: https://doi.org/10.2340/1651-226X.2025.43496

Jahreiß MC, Incrocci L, Aben KKH, De Vries KC, Hoogeman M, Hooning MJ, et al. The impact of baseline health factors on second primary cancer risk after radiotherapy for prostate cancer. Acta Oncol. 2024;63:511–7.

https://doi.org/10.2340/1651-226X.2024.24334 DOI: https://doi.org/10.2340/1651-226X.2024.24334

Tiruye T, Roder D, FitzGerald LM, O’Callaghan M, Moretti K, Beckmann K. Utility of prescription-based comorbidity indices for predicting mortality among Australian men with prostate cancer. Cancer Epidemiol. 2024;88:102516.

https://doi.org/10.1016/j.canep.2023.102516 DOI: https://doi.org/10.1016/j.canep.2023.102516